A New Jersey appeals panel has handed Merck & Co. a victory in the mass litigation over its painkiller Vioxx by barring 98 English and Welsh users of the drug from suing in the state’s courts.
The plaintiffs wanted to take advantage of New Jersey’s plaintiff-friendly laws and fee-switching rules that do not exist in the United Kingdom, the other possible forum.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
